1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Esophageal Atresia Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Esophageal Atresia Treatment Market, by Treatment Type
8.1.1. Surgical Repair Procedures
8.1.1.1. Market Revenue and Forecast
8.1.2. Non-Surgical / Supportive Care
8.1.2.1. Market Revenue and Forecast
9.1. Esophageal Atresia Treatment Market, by Complication Management
9.1.1. Stricture Management & Dilation Therapy
9.1.1.1. Market Revenue and Forecast
9.1.2. Reflux & GERD Management
9.1.2.1. Market Revenue and Forecast
9.1.3. Respiratory Complication Management
9.1.3.1. Market Revenue and Forecast
9.1.4. Long-term Feeding & Nutrition Support
9.1.4.1. Market Revenue and Forecast
10.1. Esophageal Atresia Treatment Market, by Diagnostic Modality
10.1.1. Prenatal Diagnosis
10.1.1.1. Market Revenue and Forecast
10.1.2. Postnatal Diagnostic Tools
10.1.2.1. Market Revenue and Forecast
11.1. Esophageal Atresia Treatment Market, by End-User
11.1.1. Hospitals & Surgical Centers
11.1.1.1. Market Revenue and Forecast
11.1.2. Neonatal Intensive Care Units (NICUs)
11.1.2.1. Market Revenue and Forecast
11.1.3. Outpatient & Specialty Clinics
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Treatment Type
12.1.2. Market Revenue and Forecast, by Complication Management
12.1.3. Market Revenue and Forecast, by Diagnostic Modality
12.1.4. Market Revenue and Forecast, by End-User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Treatment Type
12.1.5.2. Market Revenue and Forecast, by Complication Management
12.1.5.3. Market Revenue and Forecast, by Diagnostic Modality
12.1.5.4. Market Revenue and Forecast, by End-User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Treatment Type
12.1.6.2. Market Revenue and Forecast, by Complication Management
12.1.6.3. Market Revenue and Forecast, by Diagnostic Modality
12.1.6.4. Market Revenue and Forecast, by End-User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Treatment Type
12.2.2. Market Revenue and Forecast, by Complication Management
12.2.3. Market Revenue and Forecast, by Diagnostic Modality
12.2.4. Market Revenue and Forecast, by End-User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Treatment Type
12.2.5.2. Market Revenue and Forecast, by Complication Management
12.2.5.3. Market Revenue and Forecast, by Diagnostic Modality
12.2.5.4. Market Revenue and Forecast, by End-User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Treatment Type
12.2.6.2. Market Revenue and Forecast, by Complication Management
12.2.6.3. Market Revenue and Forecast, by Diagnostic Modality
12.2.6.4. Market Revenue and Forecast, by End-User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Treatment Type
12.2.7.2. Market Revenue and Forecast, by Complication Management
12.2.7.3. Market Revenue and Forecast, by Diagnostic Modality
12.2.7.4. Market Revenue and Forecast, by End-User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Treatment Type
12.2.8.2. Market Revenue and Forecast, by Complication Management
12.2.8.3. Market Revenue and Forecast, by Diagnostic Modality
12.2.8.4. Market Revenue and Forecast, by End-User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Treatment Type
12.3.2. Market Revenue and Forecast, by Complication Management
12.3.3. Market Revenue and Forecast, by Diagnostic Modality
12.3.4. Market Revenue and Forecast, by End-User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Treatment Type
12.3.5.2. Market Revenue and Forecast, by Complication Management
12.3.5.3. Market Revenue and Forecast, by Diagnostic Modality
12.3.5.4. Market Revenue and Forecast, by End-User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Treatment Type
12.3.6.2. Market Revenue and Forecast, by Complication Management
12.3.6.3. Market Revenue and Forecast, by Diagnostic Modality
12.3.6.4. Market Revenue and Forecast, by End-User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Treatment Type
12.3.7.2. Market Revenue and Forecast, by Complication Management
12.3.7.3. Market Revenue and Forecast, by Diagnostic Modality
12.3.7.4. Market Revenue and Forecast, by End-User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Treatment Type
12.3.8.2. Market Revenue and Forecast, by Complication Management
12.3.8.3. Market Revenue and Forecast, by Diagnostic Modality
12.3.8.4. Market Revenue and Forecast, by End-User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Treatment Type
12.4.2. Market Revenue and Forecast, by Complication Management
12.4.3. Market Revenue and Forecast, by Diagnostic Modality
12.4.4. Market Revenue and Forecast, by End-User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Treatment Type
12.4.5.2. Market Revenue and Forecast, by Complication Management
12.4.5.3. Market Revenue and Forecast, by Diagnostic Modality
12.4.5.4. Market Revenue and Forecast, by End-User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Treatment Type
12.4.6.2. Market Revenue and Forecast, by Complication Management
12.4.6.3. Market Revenue and Forecast, by Diagnostic Modality
12.4.6.4. Market Revenue and Forecast, by End-User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Treatment Type
12.4.7.2. Market Revenue and Forecast, by Complication Management
12.4.7.3. Market Revenue and Forecast, by Diagnostic Modality
12.4.7.4. Market Revenue and Forecast, by End-User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Treatment Type
12.4.8.2. Market Revenue and Forecast, by Complication Management
12.4.8.3. Market Revenue and Forecast, by Diagnostic Modality
12.4.8.4. Market Revenue and Forecast, by End-User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Treatment Type
12.5.2. Market Revenue and Forecast, by Complication Management
12.5.3. Market Revenue and Forecast, by Diagnostic Modality
12.5.4. Market Revenue and Forecast, by End-User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Treatment Type
12.5.5.2. Market Revenue and Forecast, by Complication Management
12.5.5.3. Market Revenue and Forecast, by Diagnostic Modality
12.5.5.4. Market Revenue and Forecast, by End-User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Treatment Type
12.5.6.2. Market Revenue and Forecast, by Complication Management
12.5.6.3. Market Revenue and Forecast, by Diagnostic Modality
12.5.6.4. Market Revenue and Forecast, by End-User
13.1. Cook Medical LLC
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Medtronic Plc
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Boston Scientific Corporation
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Teleflex Incorporated
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Olympus Corporation
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Applied Medical Resources Corporation
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Taewoong Medical
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. B. Braun Melsungen AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Merit Medical Systems
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. ELLA-CS
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
